Adherium has announced the release of its SmartTurbo Model 4, the next generation of the company’s adherence monitoring technology. This iteration is designed for AstraZeneca’s Turbuhaler medication.
AstraZeneca and Adherium have a long term strategic partnership to deliver scientific breakthroughs to transform the lives of people with Asthma and COPD.
Adherium’s SmartTurbo Model 4 is the company’s second SmartTurbo device to be released in two years.
The news comes hot on the heels of the U.S. FDA clearance of the company’s new SmartTouch for Symbicort® inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler, covered on our pages recently.
SmartTurbo Model 4 includes usability improvements to make the installation and removal of the Turbuhaler easier for older patients with COPD. The device also features a series of new larger buttons that help patients easily access new optional device features, including audio visual-reminders, battery monitoring, and Bluetooth low-energy (BLE) pairing. The company has also added new sensors to generate more data for monitoring and providing feedback on correct use of the inhaler for priming, inhalation, and closing of the medication at each use.
The SmartTurbo Model 4 was on show at this week’s 27th International Congress of the European Respiratory Society (ERS) in Milan, Italy.
Arik Anderson, CEO of Adherium, said: “We believe that SmartTurbo Model 4 will address a key unmet need for patients with asthma or chronic obstructive pulmonary disease by monitoring and improving adherence to their medications. We are now demonstrating the ability to design, obtain regulatory approvals, transfer to production, and release to market, on an annual cycle – improving the device with each successive generation.”